Castle Biosciences Inc To Host 2022 Investor Day Transcript
(presentation)
Thank you all for joining us today for Castle's 2022 Investor Day.
Before we begin, I would like to remind you that some of the statements made today will contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. So please take a moment to review these statements.
We'll start today by hearing from Derek Maetzold, Castle's Founder, President and CEO, and he'll discuss our overall corporate strategy. Then Dr. Brent Moody of Heritage Medical Associates, a thought leader in dermatology and Mohs surgeon will then discuss 2 of our skin cancer tests focused on risk stratification, DecisionDx-Melanoma and DecisionDx-SCC. We'll then have Dr. Matt Goldberg, dermatologist, dermatopathologist and our head Medical Director, discuss our diagnostic GEP offering, myPath Melanoma and DiffDx-melanoma. He will then give an overview of our inflammatory skin disease pipeline
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |